Point-of-care Portable Perfusion Phantom (P4)

DEVICE3 trials

Sponsors

University of Alabama at Birmingham, Ohio State University, Ohio State University Comprehensive Cancer Center

Conditions

Borderline Resectable Pancreatic Ductal AdenocarcinomaBorderline-resectable Pancreatic CancerGlioblastoma

Phase 1

DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer

Not yet recruitingNCT07705919

Ohio State University Comprehensive Cancer CenterBorderline Resectable Pancreatic Ductal Adenocarcinoma

Start: 2026-09-01End: 2027-12-31Target: 50Updated: 2026-07-15

Unknown Phase

Accurate DCE-MRI Measurement of Glioblastoma Using Point-of-care Portable Perfusion Phantom

CompletedNCT05140902

University of Alabama at BirminghamGlioblastoma

Start: 2022-03-28End: 2024-08-25Updated: 2025-02-14

DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer

RecruitingNCT06173310

Ohio State UniversityBorderline-resectable Pancreatic Cancer

Start: 2024-10-10End: 2029-03-01Target: 50Updated: 2026-02-27